QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=B1046C70A73041F45AB67844C940E1F0;jsessionid=3284B95ABC37C6629C3656CEB77556E6;jsessionid=3A5482A4E8ACBD890F122BAF1ED4E347;jsessionid=0821CAD441D2CA91E2AF2B3023CCC4ED;jsessionid=0DCA13AF6028652340F9ACAFDD75C383;jsessionid=C01D4F472D9A3A707DAC7F6D1B1D0B3C;jsessionid=68A902BC2B06B89F01122C630239E5CA (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=9A6DB3B64EC4691E87DB5822539F917C;jsessionid=021395EE77A032A88963306DAA958A91;jsessionid=B1046C70A73041F45AB67844C940E1F0;jsessionid=3284B95ABC37C6629C3656CEB77556E6;jsessionid=3A5482A4E8ACBD890F122BAF1ED4E347;jsessionid=0821CAD441D2CA91E2AF2B3023CCC4ED;jsessionid=0DCA13AF6028652340F9ACAFDD75C383;jsessionid=C01D4F472D9A3A707DAC7F6D1B1D0B3C;jsessionid=68A902BC2B06B89F01122C630239E5CA